New Issue | MicroRNA; Volume 9 Issue 1




MicroRNA publishes letters, full-length/ mini reviews, research articles, drug clinical trial studies and thematic issues on all aspects of microRNA (miRNA) research. The scope of the journal covers all experimental miRNA research and applied research in health and disease, including therapeutic, biomarkers, and diagnostic applications of MiRNA.


Articles from the journal: MicroRNA; Volume 9 Issue 1

For details on the articles, please visit this link:

Testimonial by Dr. Yi Da!


Yi Da.jpg




Journal Name: Current Drug Metabolism

Contributed Article: Serial Quantification of Urinary Protein Biomarkers to Predict Drug-induced Acute Kidney Injury

Become an Editorial Board Member (EBM) | Current Nutraceuticals


Current Nutraceuticals publishes original research articles, mini- and full-length reviews, feature articles, technical notes and thematic issues covering all aspects of nutraceuticals, from the isolation and comprehensive characterization of secondary metabolites and their synthesis to the biological activity of nutritional constituents and antioxidants, clinical, population, ethnological and agricultural studies. The journal also explicitly welcomes interdisciplinary contributions considering wider social, cultural, ethical and applied aspects of nutraceuticals and nutrition in modern society.

  • Isolation and comprehensive chemical and physical characterization of active ingredients
  • Secondary metabolites from plants and (micro-)organisms
  • Antioxidants
  • Chemoprevention
  • Biomarkers of nutrition and health
  • Chemistry of nutraceuticals, including synthesis
  • Nutrition and ageing
  • Nutrition and lifestyle
  • Nutraceuticals and drug development
  • Nutraceuticals in agriculture
  • Healthy diets
  • Nutraceuticals in Society: Wider cultural, social, ethical, ecological and economic implications

The Journal Current Nutraceuticals is interested in appointing active Editorial Board Member  on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Editorial Board Member, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field, you can recommend suitable colleagues for the same, and, if possible, send their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at: and CC:



Open Access Articles – Glutamatergic Deficits in Schizophrenia – Biomarkers and Pharmacological Interventions within the Ketamine Model

Journal Name: Current Pharmaceutical Biotechnology

Author(s): Moritz Haaf, Gregor Leicht, Stjepan Curic, Christoph Mulert*.




Graphical Abstract:




Background: The observation that N-methyl-D-aspartate glutamate receptor (NMDAR) antagonists such as ketamine transiently induce schizophrenia-like positive, negative and cognitive symptoms has led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. NMDAR hypofunction can explain many schizophrenia symptoms directly due to excitatory-to-inhibitory (E/I) imbalance, but also dopaminergic dysfunction itself. However, so far no new drug targeting the NMDAR has been successfully approved. In the search for possible biomarkers it is interesting that ketamine-induced psychopathological changes in healthy participants were accompanied by altered electro-(EEG), magnetoencephalographic (MEG) and functional magnetic resonance imaging (fMRI) signals.

Methods: We systematically searched PubMed/Medline and Web of Knowledge databases (January 2006 to July 2017) to identify EEG/MEG and fMRI studies of the ketamine model of schizophrenia with human subjects. The search strategy identified 209 citations of which 46 articles met specified eligibility criteria.

Results: In EEG/MEG studies, ketamine induced changes of event-related potentials, such as the P300 potential and the mismatch negativity, similar to alterations observed in schizophrenia patients. In fMRI studies, alterations of activation were observed in different brain regions, most prominently within the anterior cingulate cortex and limbic structures as well as task-relevant brain regions. These alterations were accompanied by changes in functional connectivity, indicating a balance shift of the underlying brain networks. Pharmacological treatments did alter ketamine-induced changes in EEG/MEG and fMRI studies to different extents.

Conclusion: This review highlights the potential applicability of the ketamine model for schizophrenia drug development by offering the possibility to assess the effect of pharmacological agents on schizophrenia- like symptoms and to find relevant neurophysiological and neuroimaging biomarkers.



For more details, please visit:

New Issue :: MicroRNA (Volume: 7, Issue: 3)


MicroRNA publishes letters, full-length research, review articles, drug clinical trial studies and thematic issues on all aspects of microRNA (miRNA) research. The scope of the journal covers all experimental miRNA research and applied research in health and disease, including therapeutic, biomarkers, and diagnostic applications of MiRNA.




Articles from the journal MicroRNA Volume 7, Issue 3:


For details on the articles, please visit this link ::

CALL FOR PAPERS – Special Thematic Issues

Forthcoming Special Issues of the journal Current Chemical Biology”




CCB -THEMATIC FLYER-Emanuele Calabrò

Guest Editor(s): Emanuele Calabrò

Tentative Publication Date: April, 2019

For more details please visit:

Email here to submit your paper:

CALL FOR PAPERS – Thematic Issue

Forthcoming Special Issue of the Journal: Current Chemical Biology





Guest Editor: Emanuele Calabrò


Hepatitis day related Articles

The Role of MicroRNA in Pathogenesis and as Markers of HCV Chronic Infection


Journal Name: Current Drug Targets

Author(s): Chang Ho Lee*, Ji Hyun Kim, Seong-Wook Lee*.



Graphical Abstract:



Hepatitis C virus (HCV) is a worldwide major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Accumulating evidence indicates that a number of microRNAs (miRNAs), which are able to exert an effect on liver biology and pathology, can regulate or be regulated by HCV infection. Many studies demonstrate that HCV utilizes host miRNAs and modulates expression of miRNAs in infected hepatocytes for its infection and propagation. In turn, host miRNAs can directly regulate HCV replication through interaction with the HCV RNA genome or by indirectly controlling the host pathways associated with the virus replication, which eventually induce HCV-related liver diseases such as liver fibrosis, hepatic cirrhosis, or HCC. Recently, extracellular miRNAs (circulating miRNAs) detected in human serum and plasma are proposed as biomarker candidates for pathological conditions due to their remarkably stable nature and the non-invasiveness of their detection. Since these circulating miRNAs exhibit consistent levels between healthy individuals but significantly changed profiles in disease conditions, considerable effort has been employed to investigate the alteration in the circulating miRNA pattern that is related with HCV infection and associated liver diseases. In this review, we summarize the features of miRNAs critical for HCVassociated liver disease initiation and progress, and discuss growing evidence that distinctive circulating miRNA patterns are related with HCV infection and associated liver diseases. These will shed light on the development of miRNA-based therapeutic modalities and non-invasive biomarkers for the diagnosis and prognosis of HCV infection and associated diseases.



For more details, Please visit:

MOST ACCESSED ARTICLE – The Use of Biomarkers in Sepsis – Current Pharmaceutical Biotechnology

Journal: Current Pharmaceutical Biotechnology

Author(s): Konstantinos Giannakopoulos*, Ursula Hoffmann, Uzair Ansari, Thomas Bertsch, Martin Borggrefe,Ibrahim Akin, Michael Behnes

Graphical Abstract:



Background: Despite the extended laboratory and clinical study of sepsis, its diagnosis remains a clinical challenge. The initiation of sepsis activates many different biochemical and immunological pathways being expressed by alterations of various molecules in human tissues. The detection and measurement of the concentration of such molecules, known as biomarkers, may be a diagnostic tool of great significance for clinicians dealing with suspected sepsis. Additionally, biomarkers may predict patients ´ outcome and may play a role in monitoring response to therapy.

Methods: Most relevant clinical and experimental biomarker studies on sepsis were retrieved and reviewed in this article.

Results: Although many biomarkers were evaluated for the diagnosis and prognosis in sepsis, until now not one has been proven to be absolutely reliable in the clinical field. Currently C-reactive proteine (CPR) and procalcitonin (PCT) are used worldwide routinely, nevertheless their values may elevate in clinical settings without sepsis, while they often fail to provide reliable prediction of the patient outcome.
Conclusion: This review outlines most relevant circulating biomarkers in sepsis.
To access the article, please visit:


Testimonial by Dr. Orfeas Liangos!


Contributed Article: Update on AKI Biomarker Patents

%d bloggers like this: